From Wikipedia, the free encyclopedia
Jump to: navigation, search
Clinical data
AHFS/Drugs.com International Drug Names
Routes of
Oral (tablets), IV
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Pharmacokinetic data
Bioavailability 5–11% (Tmax = 2 hours)
Metabolism COMT (slow O-methylation)
Biological half-life ~50 minutes (if taken orally)
Excretion Feces (~90%)[1]
Synonyms 4-[2-[6-[[2-(3,4-dihydroxyphenyl)-2-hydroxyethyl]amino]hexylamino]-1-hydroxyethyl]benzene-1,2-diol
CAS Number
PubChem CID
Chemical and physical data
Formula C22H32N2O6
Molar mass 420.499 g/mol
3D model (Jmol)
Chirality Racemic mixture
 NYesY (what is this?)  (verify)

Hexoprenaline (HEX-oh-PREN-a-leen, INN) is a selective β2 adrenergic receptor agonist used in the treatment of asthma.[2] Hexoprenaline is also used in some countries (such as Russia and Switzerland) as a tocolytic agent (i.e., labor suppressant), with the most common trade name being Gynipral.[3] [4] It is not approved by U.S. FDA.


When used as a tocolytic, hexoprenaline is contraindicated in:

It should be used with caution in people with gestational diabetes.

Drug-drug interactions[edit]

When concomitantly administered:

Hexoprenaline is contraindicated for use with monoamine oxidase inhibitors (MAOIs), tricyclic antidepressant (TCAs), ergot alkaloids, and dihydrotachysterol.[3]


  1. ^ a b "Gynipral (hexoprenaline) Full Prescribing Information". Russian State Register of Medicinal Products (in Russian). Nycomed Austria GmbH. St. Peter-Straße 25, A-4020, Linz, Austria. Retrieved 19 March 2016. 
  2. ^ Pinder, RM; Brogden, RN; Speight, ™; Avery, GS (July 1977). "Hexoprenaline". Drugs. 14 (1): 1–28. doi:10.2165/00003495-197714010-00001. PMID 195789. 
  3. ^ a b c "Gynipral (hexoprenaline) Tablets 0.5 mg, Solution for Intravenous Infusion 5 μg/mL (0.0005%)". "RLS" (РЛС): Russian Register of Medical Products (in Russian). Retrieved 19 March 2016. 
  4. ^ "GYNIPRAL Inj Lös 10 mcg/2ml". "Compendium": Swiss Register of Medical Products (in German). Retrieved 3 April 2017.